TAS-116, a Novel, Orally Bioavailable HSP90a/β Selective Inhibitor Demonstrates Highly Potent Antitumor Activity in Preclinical Models with a Favorable PK Profile

被引：3
|
作者：
Ohkubo, S. [1 ]
Muraoka, H. [1 ]
Hashimoto, A. [1 ]
Ito, S. [1 ]
Ito, K. [1 ]
Shibata, Y. [1 ]
Kanoh, A. [1 ]
Kitade, M. [1 ]
Yonekura, K. [1 ]
Utsugi, T. [1 ]
机构：
[1] Taiho Pharmaceut Co LTD, Tsukuba Res Ctr, Tsukuba, Ibaraki, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72089-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
291
引用
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [1] TAS-116, a Novel, Orally Bioavailable Highly Potent HSP90a/β Selective Inhibitor Demonstrates Favorable Tissue Distribution Properties Which Lead to Minimized Ocular Toxicity
    Kodama, Y.
    Hitotsumachi, H.
    Shibata, Y.
    Suzuki, T.
    Sakuragi, M.
    Kitade, M.
    Morita, F.
    Yonekura, K.
    Ohkubo, S.
    Utsugi, T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 89 - 89
  • [2] TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
    Ohkubo, Shuichi
    Kodama, Yasuo
    Muraoka, Hiromi
    Hitotsumachi, Hiroko
    Yoshimura, Chihoko
    Kitade, Makoto
    Hashimoto, Akihiro
    Ito, Kenjiro
    Gomori, Akira
    Takahashi, Koichi
    Shibata, Yoshihiro
    Kanoh, Akira
    Yonekura, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (01) : 14 - 22
  • [3] TAS-116, an orally available HSP90α/β selective inhibitor: Synthesis and biological evaluation.
    Uno, Takao
    Kitade, Makoto
    Yamashita, Satoshi
    Oshiumi, Hiromi
    Kawai, Yuichi
    Mizutani, Takashi
    Yoshimura, Chihoko
    Kodama, Yasuo
    Muraoka, Hiromi
    Takahashi, Kouichi
    Yonekura, Kazuhiko
    Ohkubo, Shuichi
    Utsugi, Teruhiro
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [4] TAS-116, an orally available HSP90α/β selective inhibitor, has potent antitumor activity in small cell lung cancer as a single agent and in combination with an anthracycline derivative, amrubicin.
    Muraoka, Hiromi
    Yoshimura, Chihoko
    Hashimoto, Akihiro
    Ito, Kenjiro
    Kitade, Makoto
    Yonekura, Kazuhiko
    Ohkubo, Shuichi
    Utsugi, Teruhiro
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [5] TAS1553, a novel class of RNR inhibitor, demonstrates antitumor activity in preclinical models
    Ueno, H.
    Hoshino, T.
    Tsukioka, S.
    Yano, W.
    Suzuki, T.
    Hashimoto, A.
    Miyahara, S.
    Hara, S.
    Ogino, Y.
    Ichikawa, K.
    Matsuo, K.
    Miyadera, K.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E62 - E63
  • [6] NVP-BEP800: an orally bioavailable small molecule Hsp90 inhibitor with potent in vivo antitumor activity
    Jensen, Michael
    Schoepfer, Joseph
    Massey, Andrew
    Brough, Paul
    Brueggen, Josef
    Schweitzer, Alain
    Pfaar, Ulrike
    Quadt, Corneiia
    Drysdale, Martin
    Chene, Patrick
    Garcia-Echeverria, Carlos
    CANCER RESEARCH, 2009, 69
  • [7] Preclinical Activity of the Novel Orally Bioavailable HSP90 Inhibitor NVP-HSP990 against Multiple Myeloma Cells
    Stuehmer, Thorsten
    Iskandarov, Kamol
    Gao, Zhenhai
    Bumm, Thomas
    Grella, Evelyn
    Jensen, Michael R.
    Einsele, Hermann
    Chatterjee, Manik
    Bargou, Ralf C.
    ANTICANCER RESEARCH, 2012, 32 (02) : 453 - 462
  • [8] TAS-116, a highly selective inhibitor of heat shock protein 90a/β, inhibits tumor growth in biliary tract cancer mouse models
    Ohkubo, S.
    Muraoka, H.
    Kodama, Y.
    Ito, K.
    Ito, S.
    Hashimoto, A.
    Yoshimura, C.
    Utsugi, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 191 - 191
  • [9] Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models
    Luecking, Ulrich T.
    Lefranc, Julien
    Wengner, Antje
    Wortmann, Lars
    Schick, Hans
    Briem, Hans
    Siemeister, Gerhard
    Lienau, Philip
    Schatz, Christoph
    Bader, Benjamin
    Deeg, Gesa
    von Nussbaum, Franz
    Brands, Michael
    Mumberg, Dominik
    Ziegelbauer, Karl
    CANCER RESEARCH, 2017, 77
  • [10] YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
    Xia, Yong
    Song, Xuejiao
    Li, Deliang
    Ye, Tinghong
    Xu, Youzhi
    Lin, Hongjun
    Meng, Nana
    Li, Guobo
    Deng, Senyi
    Zhang, Shuang
    Liu, Li
    Zhu, Yongxia
    Zeng, Jun
    Lei, Qian
    Pan, Youli
    Wei, Yuquan
    Zhao, Yinglan
    Yu, Luoting
    SCIENTIFIC REPORTS, 2014, 4
12345